The first intron (intron I) of the human factor IX gene, which has been previously suggested of having an expression-augmenting activity, was systematically studied for its potential enhancer activity. When tested with the chloramphenicol acetyltransferase expression vector with a minimal factor IX promoter, subregions of intron I showed only marginal enhancing activities (1.7-1.9-fold enhancement at the highest). Smaller subregions encompassing nucleotides 5660-6350 of the intron sequence even showed some weak negative regulatory activities (50% suppression at the highest), while a cytomegalovirus enhancer sequence, which was used as the positive control, had a 7-fold enhancement. A set of three factor IX minigene expression vectors with the same factor IX promoter were then constructed: p-416FIXc which contained the factor IX cDNA, p-416FIXm1 which contained the factor IX cDNA with a largely truncated intron I, and p-416FIXm2 which contained the factor IX cDNA with the intron I sequence further truncated. The p-416FIXm1 and p-416FIXm2 constructs showed 7-9-fold higher expression activities than p-416FIXc. The elevated factor IX antigen levels agreed well with the grossly elevated factor IX clotting activity and mRNA levels. These results indicate that the expression enhancing activity of intron I is not due to specific enhancer elements present in the intron subsequences, but is due to functional splicing sequences present in the precursor mRNAs produced from the minigene constructs containing intron I. By being efficiently assembled into spliceosome complexes, transcripts with splicing sequences may be better protected in the nucleus from random degradations than those without such sequences.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				D. E. Sabatino, E. Armstrong, S. Edmonson, Y.-L. Liu, M. Pleimes, J. Schuettrumpf, J. Fitzgerald, R. W. Herzog, V. R. Arruda, and K. A. High Novel hemophilia B mouse models exhibiting a range of mutations in the Factor IX gene Blood, November 1, 2004; 104(9): 2767 - 2774. [Abstract] [Full Text] [PDF]

				C. S. Manno, A. J. Chew, S. Hutchison, P. J. Larson, R. W. Herzog, V. R. Arruda, S. J. Tai, M. V. Ragni, A. Thompson, M. Ozelo, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B Blood, April 15, 2003; 101(8): 2963 - 2972. [Abstract] [Full Text] [PDF]

				K. Zhang, S. Kurachi, and K. Kurachi Limitation in Use of Heterologous Reporter Genes for Gene Promoter Analysis. SILENCER ACTIVITY ASSOCIATED WITH THE CHLORAMPHENICOL ACETYLTRANSFERASE REPORTER GENE J. Biol. Chem., February 7, 2003; 278(7): 4826 - 4830. [Abstract] [Full Text] [PDF]

				G. Schiedner, S. Hertel, M. Johnston, V. Biermann, V. Dries, and S. Kochanek Variables Affecting In Vivo Performance of High-Capacity Adenovirus Vectors J. Virol., February 15, 2002; 76(4): 1600 - 1609. [Abstract] [Full Text] [PDF]

				A. C. Nathwani, A. Davidoff, H. Hanawa, J.-F. Zhou, E. F. Vanin, and A. W. Nienhuis Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA Blood, March 1, 2001; 97(5): 1258 - 1265. [Abstract] [Full Text] [PDF]

				J.-S. Jeon, S. Lee, K.-H. Jung, S.-H. Jun, C. Kim, and G. An Tissue-Preferential Expression of a Rice alpha -Tubulin Gene, OsTubA1, Mediated by the First Intron Plant Physiology, July 1, 2000; 123(3): 1005 - 1014. [Abstract] [Full Text]

				A. K. Malik, P. E. Monahan, D. L. Allen, B.-G. Chen, R. J. Samulski, and K. Kurachi Kinetics of Recombinant Adeno-Associated Virus-Mediated Gene Transfer J. Virol., April 15, 2000; 74(8): 3555 - 3565. [Abstract] [Full Text]

				J. N. Hagstrom, L. B. Couto, C. Scallan, M. Burton, M. L. McCleland, P. A. Fields, V. R. Arruda, R. W. Herzog, and K. A. High Improved muscle-derived expression of human coagulation factor IX from a skeletal actin/CMV hybrid enhancer/promoter Blood, April 15, 2000; 95(8): 2536 - 2542. [Abstract] [Full Text] [PDF]

				K. Kurachi and S. Kurachi Genetic Mechanisms of Age Regulation of Blood Coagulation : Factor IX Model Arterioscler. Thromb. Vasc. Biol., April 1, 2000; 20(4): 902 - 906. [Abstract] [Full Text] [PDF]

				S. Kurachi, Y. Deyashiki, J. Takeshita, and K. Kurachi Genetic Mechanisms of Age Regulation of Human Blood Coagulation Factor IX Science, July 30, 1999; 285(5428): 739 - 743. [Abstract] [Full Text]

				H. Nakai, R. W. Herzog, J. N. Hagstrom, J. Walter, S.-H. Kung, E. Y. Yang, S. J. Tai, Y. Iwaki, G. J. Kurtzman, K. J. Fisher, et al. Adeno-Associated Viral Vector-Mediated Gene Transfer of Human Blood Coagulation Factor IX Into Mouse Liver Blood, June 15, 1998; 91(12): 4600 - 4607. [Abstract] [Full Text] [PDF]

				K.-J. Li and H. Garoff Packaging of intron-containing genes into retrovirus vectors by alphavirus vectors PNAS, March 31, 1998; 95(7): 3650 - 3654. [Abstract] [Full Text] [PDF]

				R. W. Herzog, J. N. Hagstrom, S.-H. Kung, S. J. Tai, J. M. Wilson, K. J. Fisher, and K. A. High Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus PNAS, May 27, 1997; 94(11): 5804 - 5809. [Abstract] [Full Text] [PDF]